Where’s the line between consumer advocacy and online harassment?

Considering healthcare is often, literally, a matter of life and death, disagreements between patient and physician can escalate. A recent feature in USA Today looked at one case to explore the blurred line between consumer advocacy and online harassment.

David Altoon recently settled felony charges for violating a stalking protection order from his former surgeon, agreeing to pay $100 after a 10-year battle over a procedure that left Altoon incontinent and impotent.

USA Today details the story of Altoon and Jihad Kaouk, a urologist with the Cleveland Clinic—using it to highlight ongoing issues with online reviews and social media posts that patients see as consumer advocacy but some physicians might view as harassment.

The disconnect can leave both sides feeling helpless. Patients, when they feel wronged, face hospitals and doctors with legal teams and seemingly endless resources. Physicians, when faced with negative reviews, often have no recourse to address complaints or issues, while such information is available for everyone to find through an online search.

Read the full story at the link below:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.